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Theepidermalgrowthfactorreceptor(EGFR)isoverexpressedinthevastmajorityofcasesofsquamouscellcarcinomaofthehead
andneck(SCCHN).AhighEGFRexpressionisassociatedwithanunfavorableprognosis.Cetuximabisachimerichuman/murine
IgG1 antibody which binds with high aﬃnity to the EGFR. It is the only targeted agent which got approval for the treatment of
SCCHN from the regulatory agencies of Europe and the United States, both in locoregionally advanced disease, in association
with radiation, and in recurrent/metastatic disease. The outcome of trials involving other EGFR-directed monoclonal antibodies,
that is, zalutumumab and panitumumab, was consistent with the results with cetuximab. However these trials failed to meet their
primary endpoint. The results with EGFR-directed tyrosine kinase inhibitors have been disappointing. Other potential targets for
treatment in SCCHN include the entire ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), the
insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (IR), histone deacetylases (HDAC), the mammalian target of
rapamycin (mTOR), the platelet-derived growth factor receptor (PDGFR), heat-shock protein 90 (HSP90), nuclear factor-kappa
B( N F - κB), aurora A or B, and phosphatidylinositol 3-kinase (PIK3CA).
1.Introduction
Worldwide, squamous cell carcinoma of the head and neck
(SCCHN) is the sixth most common cancer and is diagnosed
in more than 600,000 patients each year [1]. A better under-
standing of its biology has been accompanied by the intro-
duction of a large and rapidly expanding number of targeted
agentsintoitsmanagementstrategies[2].Plannedandongo-
ing trials in SCCHN involving targeted agents are summa-
rized in Tables 1, 2, 3,a n d4 [3]. Potential targets include
the epidermal growth factor receptor (EGFR) and the ErbB
family, the vascular endothelial growth factor (VEGF) and
its receptor (VEGFR), Insulin-like Growth Factor 1 Recept-
or (IGF-1R), insulin receptor (IR), histone deacetylase
(HDAC),mammaliantargetofrapamycin(mTOR),platelet-
derived growth factor (PDGFR), Heat-shock protein 90
(HSP90), Nuclear factor-kappa B (NF-κB), aurora A or B,
phosphatidylinositol 3-kinase (PIK3CA).
2. EGFR-DirectedTherapies
The Epidermal Growth Factor Receptor (EGFR) belongs to
the ErbB family of receptors which includes four mem-
bers: EGFR/ErbB1, ErbB2/Her2/neu, ErbB3, and ErbB4.
EGFR consists of an extracellular N-terminal ligand-binding
domain, a hydrophobic transmembrane domain, and a
C-terminal intracellular domain, which includes the tyrosine
kinase domain and the autophosphorylation sites. The Epi-
dermal Growth Factor Receptor (EGFR) is overexpressed in
thevastmajorityofcasesofSquamousCellCarcinomaofthe
H e a da n dN e c k( S C C H N )[ 4]. A high EGFR expression and
an increased EGFR gene copy number are associated with
an unfavorable prognosis [5–7]. Two of the potential EGFR
targeting strategies that are currently in use in the treatment
of SCCHN are the monoclonal antibodies directed at the
extracellular domain of the receptor and the small molecule
and ATP-competitive tyrosine kinase inhibitors (TKIs).2 ISRN Oncology
Table 1: Planned or ongoing trials with cetuximab in SCCHN.
Trial phase Disease setting Associated treatment Comparator
Phase III
LA resectable TP before surgery Surgery + RT
LA RT (after TPF ICT) RT + P
LA RT after TPF RT + P or CRT
LA HPV + OPH RT P
LA resected RT none
Randomized phase II
LA RT P
LA TPF or paclitaxel + carbo
LA Adjuvant after CRT + cetuximab none
R/M Temsirolimus
LA ICT TPF or paclitaxel/P
Single arm phase II
L A R T+( Po rc a r b o )+N A B P
LA (Accelerated) RT
LA ICT TPF
LA ICT TP
LA ICT Paclitaxel/P → RT
LA after TPF ICT RT
LA resected CRT
LA after carbo/paclitaxel ICT RT + P
Adjuvant after CRT None
Local recurrence BNCT
Local recurrence RT
Local recurrence RT + P
Local recurrence Radiosurgery
Reirradiation RT
R/M carbo/P + pemetrexed
R/M TP
R/M 2nd carbo + vinorelbine
LA: locoregionally advanced; R/M: recurrent/metastatic; RT: radiotherapy; P: cisplatin.
T: docetaxel; F: 5-ﬂuorouracil; carbo: carboplatin; ICT: induction chemotherapy.
2nd: second line; NABP: nanoparticle albumin-bound paclitaxel.
BNCT: boron neutron capture therapy; CRT: concurrent chemoradiation; OPC: oropharyngeal cancer.
2.1. EGFR-Directed Monoclonal Antibodies
2.1.1. Cetuximab. Cetuximab is the only targeted agent that
got approval by the Food and Drug Administration and the
European Medicines Agency for the treatment of SCCHN
[8, 9] and is still under active investigation in this disease [3]
(Tables 1 and 2). Cetuximab is a chimeric human/murine
IgG1 antibody which binds with higher aﬃnity to the
EGFR than the natural ligands EGF and TNF-α, thereby
disrupting EGFR signaling pathways. Another mechanism
that contributes to the antitumor activity of cetuximab is
depletion of the targeted receptors from the cell surface. The
availability of EGFR on the cell surface is reduced, and the
receptor is downregulated [10, 11]. Finally, cetuximab’s con-
struction on an IgG1 framework potentially allows the drug
to mediate antibody-dependent cell-mediated cytotoxicity
(ADCC) via natural killer (NK) cells and macrophages [12].
Cetuximab is administered once a week at an initial loading
of 400mg/m2 followed by a weekly dose of 250mg/m2 [8].
Therecommendeddose wasusedin thecetuximabstudiesin
SCCHN studies mentioned below, unless stated otherwise.
2.2. Cetuximab in Locoregionally Advanced SCCHN. Bonner
et al. [13, 14] conducted a multinational, randomized study
comparing radiotherapy alone with radiotherapy plus cetu-
ximab in 424 patients with stages III or IV, nonmetastatic,
measurable squamous cell carcinoma (SCC) of the orophar-
ynx, hypopharynx, or larynx. Investigators were required
to select one of three radiotherapy-fractionation regimens
before patient registration: 70.0Gy in 35 daily fractions
of 2.0Gy/fraction, 5 fractions/week for 7 weeks, or two
daily fractions of 1.2Gy/fraction up to 72.0–76.8Gy in 60–
64 fractions, 10 fractions/week for 6–6.5 weeks, or a con-
comitant boost regimen (72.0Gy in 42 fractions: 32.4Gy;
1.8Gy/fraction, 5 fractions/week for 3.6 weeks followed
by a morning dose of 21.6Gy in fractions of 1.8Gy, 5
fractions/week for 2.4 weeks and an afternoon dose of
18.0Gyinfractionsof1.5Gy,5fractions/weekfor2.4weeks).ISRN Oncology 3
Table 2: Targeted agents under investigation in combination with cetuximab.
Trial phase Associated Compound Target/mechanism of
action Disease setting Administration Associated treatment
Randomized
phase III
With or without 0S1-906 IGF-1R/IR R/M platinum refractory po
With or without E7050 VEGFR-2; c-MET R/M platinum refractory po
With or without
bevacizumab VEGF LA iv Pemetrexed + RT
With or without
everolimus mTOR LA po Paclitaxel + P IC
Single arm
phase II
Sorafenib CRAF; BRAF; c-KIT; FLT-3;
VEGFR-2/3; PDGFR-β R/M po
Temsirolimus mTOR R/M iv P
PX-866 Phosphoinositide-3-kinase R/M po
Everolimus mTOR R/M po Carbo
Bevacizumab VEGF R/M iv
Bevacizumab VEGF LA iv (TP) → RT + P
EMD1201081 Toll-like receptor 9 agonist R/M 2nd sc
Lenalidomide Immunomodulating agent R/M; solid tumors po
Dasatinib BCR-ABL; Src; c-KIT; EPH;
PDGFRβ LA po RT (±P)
BMS-754807 IGF-1R/IR solid tumors po
Erlotinib EGFR R/M po carbo + paclitaxel
EGFR Antisense DNA EGFR Intratumoral RT
Phase l
Everolimus mTOR LA po
Lenalidomide Immunomodulating agent R/M po RT + P
IPI-926 Smoothened, hedgehog
pathway R/M po
VTX-2337 Toll-like receptor 8 agonist R/M sc
MM-121 ErbB3 Advanced tumors iv Irinotecan
Lapatinib EGFR/HER2 Solid tumors po
RO5479599∗ HER-3 HER-3 +tumors iv
Sunitinib PDGFRα/β; VEGFRl-3;
KIT; FLT3; CSF-1R; RET Local recurrence po RT
Vorinostat HDACi LA po RT + P
mTOR:mammaliantargetofrapamycin;LA:locoregionallyadvanced;po:peros;iv:intravenously;RT:radiotherapy;EGFR:epidermalgrowthfactorreceptor;
P: cisplatin; carbo: carboplatin; T: docetaxel; R/M: recurrent/metastati c ;O P H :o r o p h a r y n g e a lc a n c e r ;c - M E T :h e p a t o c y t eg r o w t hf a c t o rr e c e p t o r ;
HDACi: histone deacetylase inhibitor; IGF-1R/IR: insulin-like growth factor-l/insulin receptor.
PDGFRβ: platelet-derived growth factor recpetor β; BRAF: serine/threonine-protein kinase B-Raf; c-KIT: mast/stem cell growth factor receptor.
∗: RO5479599 a lone or with erlotinib or with cetuximab.
Uninvolved nodal areas of the neck were treated with 50 to
54Gy, depending on the fractionation regimen used. Gross
nodal disease received the same dose as the primary tumor.
Inthegroupassignedtoreceiveradiotherapypluscetuximab,
cetuximab was initiated one week before radiotherapy at a
loading dose of 400mg/m2, followed by a weekly dose of
250mg/m2 for the duration of radiotherapy. The median
duration of locoregional control (primary endpoint) was
24.4 months in patients treated with cetuximab plus radio-
therapy and 14.9 months in patients treated with radiother-
apy alone (hazard ratio (HR) for locoregional progression or
death, 0.68; P = 0.005). The one-, two-, and three-year rates
oflocoregionalcontrolachievedwithradiotherapypluscetu-
ximab (63, 50, and 47%), were signiﬁcantly higher than
those achieved with radiotherapy alone (55, 41, and 34%,
resp.). Median overall survival (OS) for patients treated with
cetuximab and radiotherapy was 49.0 months versus 29.3
monthsintheradiotherapy-alonegroup(HRfordeath:0.73;
P = 0.018). Grade ≥2 rash was associated with an improv-
ed survival [13]. In this pivotal trial, the addition of
cetuximabdidnotleadtoanincreasedincidenceofradiation
dermatitis. However, as there is only one randomized phase
III trial with cetuximab-based bioradiation as opposed to
theabundanceofdatasupportingcisplatin-basedconcurrent
chemoradiation(CRT)[15,16],thelattercontinuestorepre-
sent the standard of care for medically ﬁt patients with loco-
regionally (LA) SCCHN, who can tolerate platinum-based
therapy. The addition of cetuximab to cisplatin-based CRT
does notfurtherimprovetheoutcome.InRadiationTherapy
Oncology Group (RTOG) 0522 [17], 895 evaluable patients4 ISRN Oncology
Table 3: Targeted agents under investigation in SCCHN.
Trial phase Compound Target/mechanism of action Disease setting Administration Associated treatment
Randomized
phase lll
INGN 201 p53 gene R/M iv PF
Bevacizumab VEGF R/M iv platin-based doublet
Reovirus serotype 3 dearing Virus R/M platinum
refractory iv Placebo
Phase ll
Temsirolimus mTOR R/M iv Carbo + paclitaxel
PX-866 Phosphoinositide-3-kinase Solid tumors po T
Everolimus mTOR R/M po (T)
Everolimus mTOR LA po Carbo + paclitaxel
BBI608 Cancer stem cells Advanced
malignancies po Paclitaxel
Sorafenib CRAF; BRAF; c-KIT; FLT-3;
VEGFR-2/3; PDGFR-β R/M po
Cediranib VEGFR-2/3 R/M po
Tadalaﬁl Phosphodiesterase-5 inhibitor R/M po
Fostamatinib syk Solid tumors po
LY2523355 Mitotic kinesin Eg5 inhibitor Solid tumors iv
Vorinostat HDACi R/M po Capecitabine
Gossypol Bcl-2 R/M po T
Pazopanib VEGFRl-3; PDGFRα/β;
FGFR1,3,4; KIT; RET R/M po
ACE-041 ALK1 R/M second line sc
Axitinib VEGFRl-3; c-KIT; PDGFR R/M po
Dacomitinib Pan-ERBB inhibitor R/M platinum
refractory po
Phase l
MAGE-A3/HPV 16 Vaccine R/M
MLN9708 Proteasome inhibitor Solid tumors po
4SC-205 Mitotic kinesin Eg5 inhibitor Advanced
malignancies po
SAR566658 HuDS6 + DM4∗ DS6-positive
tumors iv
MEHD7945A EGFR/HER3 Epithelial
tumors iv
CUDC-101 HDACi; EGFR; HER2 LA po RT + P
RT: radiotherapy; T: docetaxel; P: cisplatin; HDACi: histone deacetylase inhibitor; LA: locoregionally advanced; R/M: recurrent/metastatic.
∗Tumor-associated sialoglycotope CA6 (huDS6) conjugated to the cytotoxic maytansinoid DM4.
Syk: spleen tyrosine kinase; po: per os; iv: intravenously.
ALK1: activin receptor-like kinase 1 (ALK1).
with stage III/IV nonmetastatic SCCHN were randomized
between chemoradiation (72Gy in 42 fractions over 6 weeks
plus cisplatin 100mg/m2 on days 1 and 22) or the same
regimen plus weekly cetuximab. At the time of the third
interim analysis after 337 events and after a median followup
of 2.4 years for the surviving patients, the conditional power
of the trial becoming positive was below 10%, triggering
early reporting. Over 90% of the patients received the plan-
ned two doses of cisplatin in both arms. The 2-year pro-
gression-free survival (PFS), (primary endpoint) was 64.3%
with chemoradiation and 63.4% with chemoradiation plus
cetuximab (HR: 1.05; 95% conﬁdence interval (CI): 0.84–
1.29; P = 0.67). The 2-year OS was 79.7 and 82.6%, respect-
ively (HR: 0.87; 95% CI: 0.66–1.15; P = 0.17). The estimat-
ed 2-year locoregional relapse rate was 19.8 and 24.5%,
respectively (P = 0.92). The 2-year distant metastasis rate
was 12 and 7.6%, respectively (P = 0.07). Overall, there
was no diﬀerence regarding acute grade 3/4 acute toxicities
between both arms. However, grade 3/4 mucositis (43 versus
33%)andin-ﬁelddermatitis(25versus15%)wasmorecom-
mon with the addition of cetuximab. Grade 3/4 dermatitis
outside the radiation ﬁeld occurred in 19% of the patients
treated with cetuximab.
The TREMPLIN trial [18] is a randomized phase II study
in patients with SCC of the larynx or hypopharynx suitable
for total laryngectomy. After three 3 weekly cycles of TPF
(docetaxel 75mg/m2 and cisplatin 75mg/m2 on day 1 fol-
lowed by 5-FU 750mg/m2/day, days 1–5), patients who
obtainedatleastapartialresponse(82%ofthepatients)were
randomized to receive radiotherapy (70Gy in 35 fractionsISRN Oncology 5
Table 4: EGFR-directed targeted agents under investigation in SCCHN (other than cetuximab).
Trial phase Compound Disease setting Associated treatment Comparator
Phase III
Monoclonal Antibodies
Nimotuzumab LA resected RT + P Placebo
LA RT None
Zalutumumab nonmetastatic RT (±P) None
Tyrosine kinase inhibitors
Lapatinib∗ resected high risk Placebo
Afatinib∗ LA and NED after RT + P (+S) Placebo
LA after resection and RT + P Placebo
R/M platinum-refractory Methotrexate
Randomized phase II
Tyrosine kinase inhibitors
Erlotinib LA RT + P None
Erlotinib R/M TP Placebo
Phase II
Monoclonal antibodies
Panitumumab R/M Paclitaxel
Nimotuzumab LA RT+ P
LA (T) PF ICT
SYM-004∗∗∗ R/M platinum-refractory
Tyrosine kinase inhibitors
Lapatinib∗ LA RT
Lapatinib∗ R/M Capecitabine
Erlotinib LA RT (+T)
LA resected RT+ P
Local recurrence/2nd primary RT + pemetrexed
Local recurrence
Phase I
Monoclonal antibodies
ABT-806∗∗ Solid tumors
R05083945 or cetuximab Operable
NED: no evidence of disease; S: lymph node resection.
CRT: concurrent chemoradiation; ICT: induction chemotherapy.
T: docetaxel; P: cisplatin.
∗Dual EGFR/HER2 inhibitor. ∗∗Targets also EGFRvIII. ∗∗∗Recombinant IgG1 antibody product consisting of two antibodies against EGFR.
over 7 weeks) either with cisplatin 100mg/m2 on days 1, 22,
and 43 or with weekly cetuximab. The treatment compliance
was better in the cetuximab arm with 71% of the patients
receivingallplannedcetuximabadministrations.Forty-three
percent of the patients received three cycles of cisplatin, and
83% received 2 cycles. There was no diﬀerence in grade
3/4 mucosal toxicity, but grade 3/4 in-ﬁeld dermatitis was
more frequently observed with cetuximab (57 versus 26%;
P<0.001). Grade 1 renal dysfunction at last evaluation
was observed in 22.4% of the patients treated with cisplatin.
The larynx preservation rate 3 months after treatment (pri-
mary endpoint) was 95% with cisplatin versus 93% with
cetuximab. The locoregional failure rate after a median fol-
lowup of 36 months was 11.7% with cisplatin and 21.4%
with cetuximab. However, more salvage laryngectomies were
performed in the cetuximab arm, resulting in a similar
ultimate locoregional failure rate in the two arms (10%
versus8.9%).The2-yearlaryngoesophagealdysfunction-free
survival was 79% with cisplatin versus 71% with cetuximab
(P = 0.3).
Seiwert et al. [19] randomized 110 patients with LA
SCCHN, who had received 2 cycles of carboplatin, paclitaxel,
and cetuximab as induction chemotherapy, between weekly
cetuximab in combination with either 5-FU, hydroxyurea,
and hyperfractionated week-on week-oﬀ radiotherapy (72–
74Gy) (CetuxFHX), or cisplatin, accelerated radiation with
concomitant boost (CetuxPX) (72Gy). After a median
followup of 21 months, 2-year OS rates were 89.5% with
CetuxFHX and 91.4% with CetuxPX arm. Two-year PFS
rates were 82.3% and 89.7%, respectively (P = 0.18). Grade
≥ 3 mucositis was present in 91.1% (CetuxFHX) and 94.3%
(CetuxPX) of patients; grade ≥ 3 dermatitis in 82.1% and
50.9%, respectively. Ninety-ﬁve percent of patients complet-
ed therapy, demonstrating that cetuximab can be incorpo-
rated safely in both CRT platforms.
Argiris et al. [20] enrolled 32 patients in a phase I study
combining pemetrexed, cetuximab and radiotherapy in poor
prognosis head and neck cancer. Cohort A included patients
who had not been previously irradiated, while cohort
B included patients who had received prior irradiation.6 ISRN Oncology
Pemetrexed was administered on days 1, 22, and 43. The
maximum tolerated dose (MTD) of pemetrexed was 500mg
in cohort A and 350mg/m2 in cohort B. Grade 3/4 neutrope-
nia was common (50% in cohort A and 33% in cohort B)
and febrile neutropenia was the most frequent doselimiting
toxicity. Prophylactic antibiotics are recommended. Grade
3/4 mucositis was observed in 8 of the 9 patients treated at
the MTD in cohort A [20].
In Eastern Cooperative Oncology Group (ECOG) E2303
[21], 63 patients with resectable stage III/IV SCCHN, were
treated with 6-week cycles of paclitaxel, carboplatin at an
AUCof2andcetuximab,followedbyCRT(weeklypaclitaxel,
30mg/m2, carboplatin AUC 1, and cetuximab). If at week
14, after a radiation dose of 50Gy, tumor was still present
on biopsy, salvage surgery was performed. In case of a
negative biopsy (91% of the patients), CRT was continued
to a total dose of 68–72Gy. Two-year PFS and OS rate were
82 and 66%, respectively. A local recurrence occurred in
17.5% of the patients. Jordan et al. [22] treated 152 T3-T4
SCCHN patients with three 3-week cycles of TPF (docetaxel
75mg/m2 on day 1, cisplatin 35mg/m2 on days 1 and 2,
and 5-FU 750mg/m2/day, as a continuous infusion, days 1–
5, with pegﬁlgrastim support) followed by chemoradiation
(63Gy in 35 fractions of 1.8Gy over 7 weeks and weekly
cisplatin, 40mg/m2) plus weekly cetuximab. The complete
response rate in the 142 patients, who were evaluated after
the completion of therapy, was 57%. Grade 3/4 toxicities
occurred in 34/142 patients (24%). In 15 patients, CRT had
to be interrupted due to dermatitis.
2.2.1. Maintenance Treatment. Ferris et al. [23]t r e a t e d3 4
LA SCCHN patients with three 3-weekly cycles of cisplatin
75mg/m2 and docetaxel 75mg/m2 plus weekly cetuximab
followedbyCRT(70Gyin2Gyfractionsover7weeks,week-
ly cisplatin 30mg/m2) plus weekly cetuximab, followed by
weeklycetuximabmaintenancefor6months.The3-yearPFS
rate was 70%.
Mesia et al. [24] studied the role of cetuximab mainte-
nance therapy in patients with LA SCC of the oropharynx.
Ninety-one patients were randomized. Patients in group A
were treated concomitant radiotherapy, 69.9Gy in 28 days,
plus weekly cetuximab. Patients in group B received an addi-
tional 12-week administrations of cetuximab. The locore-
gional control rate at 1 year (primary endpoint) was 56.8%
with bioradiation and 60.5% with bioradiation followed by
cetuximab maintenance. At 1 year, event-free survival rates
were55.6and60.9%,respectively,andOSrateswere75.6and
87%, respectively.
2.3. Cetuximab in Recurrent/Metastatic SCCHN
2.3.1. First-Line Treatment. In the EXTREME trial (Erbitux
in First-Line Treatment of Recurrent or Metastatic Head
a n dN e c kC a n c e r )[ 25], 442 patients with previously
untreated R/M SCCHN were randomized to receive cisplatin
100mg/m2 or carboplatin at an area under the curve (AUC)
of 5mg/mg/min as an 1-hour infusion, followed by 5-FU
1000mg/m2 day for 4 days as a continuous infusion every
3 weeks for a maximum of 6 cycles, either alone or in com-
bination with cetuximab. The use of cisplatin or carboplatin
was at the discretion of the investigator. After a maximum
of six cycles of chemotherapy, patients in the cetuximab
group who had at least stable disease received cetuximab
monotherapy until disease progression or unacceptable toxic
eﬀects, whichever occurred ﬁrst. Cross-over was not allow-
ed. The median overall survival (primary endpoint) was 10.1
months (95% CI: 8.6–11.2) in the cetuximab group and 7.4
months (95% CI: 6.4–8.3) in the chemotherapy-alone group
(HR for death: 0.80; 95% CI: 0.64–0.99; P = 0.04). The
median followup was 19.1 months in the cetuximab group
and 18.2 months in the chemotherapy-alone group. Median
PFS was 5.6 months and 3.3 months for the combined
group and the chemotherapy alone group, respectively (HR
for progression: 0.54; 95% CI: 0.43–0.67; P<0.001). The
overall response rate (ORR) was 36 and 20%, respectively
(odds ratio (OR): 2.33; P<0.001), and the disease control
rate (DCR) was 80 and 60%, respectively (OR: 2.88; P<
0.001). Among the 100 patients who received cetuximab as
maintenance treatment, the median PFS was 12 weeks from
the start of maintenance treatment. The safety proﬁle of the
study treatment was consistent with that expected for the
agents used, with no signiﬁcant diﬀerence in the inciden-
ce of grades 3 or 4 adverse events between treatment arms.
However, there were 9 cases of sepsis in the cetuximab
group, as compared with 1 case in the chemotherapy-alone
group (P = 0.02), and there were 11 cases of hypomagne-
semia in the cetuximab group, as compared with 3 cases in
the chemotherapy-alone group (P = 0.05). Grade 3 skin
reactions were seen in 9% of the patients who received cetu-
ximab. There were four grade 3 and two grade 4 infusion-
related reactions after cetuximab [25]. ECOG [26]r a n d o m -
ized 117 R/M SCCHN patients to receive cisplatin 100m/m2
every 4 weeks plus either weekly cetuximab (group A) or
placebo (group B). Primary endpoint was PFS. Median PFS
was 4.2 months in arm A and 2.7 in arm B (HR: 0.78; 95%
CI: 0.54–1.12; P = 0.09). Median OS was 9.2 months in arm
A and 8.0 months in arm B (P = 0.21). The ORR was 26%
and 10%, respectively (P = 0.03) [26].
Hitt et al. [27] treated 46 patients with weekly cetuximab
and paclitaxel 80mg/m2 as ﬁrst-line regimen for recurrence
of metastatic SCCHN. The ORR and DCR were 54 and 80%,
respectively. Median PFS and OS were 4.2 and 8.1 months,
respectively. Common grade 3/4 adverse events were acne-
like rash (24%), asthenia (17%), and neutropenia (13%)
[27]. In Groupe d’Oncologie Radioth´ erapie Tˆ ete Et Cou
(GORTEC) 2008–03 [28], 54 patients who had not received
prior chemotherapy for R/M SCCHN were treated with
docetaxel 75mg/m2 and cisplatin 75mg/m2 every 3 weeks
and weekly cetuximab, up to 4 cycles, followed by cetuximab
maintenance in the absence of disease progression. Patients
received prophylactic lenograstim. The ORR and DCR were
51.9 and 96.1%, respectively. At time of reporting, 65%
of the patients were still alive, and median OS exceeded
11 months. High EGFRvIII and amphiregulin expression
levels identify SCCHN patients who are less likely to beneﬁt
from combination treatment with cetuximab and docetaxel
[29].ISRN Oncology 7
2.3.2. Second-Line Treatment. Three phase II trials examined
the role of cetuximab in platinum-refractory or platinum-
resistant disease [30–33]. Responses (10–13%) were ob-
served irrespective of reintroducing the originally used plati-
num compound to which they had become refractory or
resistant. The survival of around 6 months achieved with
cetuximab in platinum-refractory disease was found similar
to that seen in ﬁrst-line therapy in R/M-SCCHN and repre-
sented an increase in survival of 2.5 months compared with
platinum-refractory historical controls [34]. Based on these
results and particularly considering the fact that about 50%
ofthepatientsshoweddiseasecontrol,cetuximabmonother-
apy seems to be an option for patients with R/M SCCHN
who have progressed on platinum-based chemotherapy.
Fury et al. [35]randomized61patients,whohadreceived
≤2 prior cytotoxic chemotherapy regimens for R/M SCCHN
t or e c e i v ec e t u x i m a be v e r y2w e e k sa te i t h e r5 0 0( A )o r
750mg/m2 (B). The ORR was 11% in both arms. PFS was
also similar (65 days versus 57 days). Median OS was 8.1
months. Cetuximab 500mg/m2 every 2 weeks seemed to
yield similar eﬃcacy and tolerability as conventional weekly
dosing for patients with R/M SCCHN. However, it is unclear
how many of the patients in this study had platinum-refrac-
tory disease. There is no apparent eﬃcacy advantage associ-
ated with dose escalation to 750mg/m2 Q2W.
2.3.3. Zalutumumab. Zalutumumab is a human IgG1 mon-
oclonal antibody targeting EGFR. Machiels et al. [36]r a n d o -
mly allocated 286 eligible incurable SCCHN in a 2:1 ratio to
receive either zalutumumab plus best supportive care (zalu-
tumumab group) or best supportive care with optional
methotrexate (control group). Eligible were patients with
progressive disease according to RECIST conﬁrmed by an
independent review committee during or within 6 months
after the failure of platinum-based chemotherapy (at least
two cycles of cisplatin [≥60mg/m2 p e rc y c l e ]o rc a r b o p l a t i n
[≥250mg/m2 per cycle] with an interval between the cycles
of <4 weeks). Also eligible were patients with platinum
intolerance which was deﬁned as discontinuation or dose
reduction of platinum-based chemotherapy due to adverse
or toxic eﬀects, irrespective of response. The dose of zalu-
tumumab was titrated according to rash. Patients were given
an initial loading dose of 8mg/kg followed up by two week
doses of 4mg/kg by intravenous infusion in 1h. After the
ﬁrst three administrations, in patients with no rash or grade
1 rash, the dose was increased by 4mg/kg every 2 weeks up
to a maximum dose of 16mg/kg. Patients with grade 2 rash
remained at the same dose. Treatment was withheld from
patients with grade 3 rash until rash resolved to grade 1.
Seventy-two percent of the control patients received metho-
trexate from the initiation of the trial, and a further 6%
started methotrexate during the trial. Median OS (primary
endpoint) was 6.7 months (95% CI: 5.8–7.0) in the zalu-
tumumab group and 5.2 months (95% CI: 4.1–6.4) in
the control group (hazard ratio (HR) for death, stratiﬁed
by WHO performance status: 0.77; 97.06% CI: 0.57–1.05;
unadjustedP = 0.0648).Progression-freesurvivalwaslonger
inthezalutumumabgroupthaninthecontrolgroup(HRfor
progression or death, stratiﬁed by WHO performance status:
0.63; 95% CI: 0.47–0.84; P = 0.0012). The most common
grade 3/4 adverse events were rash (21% of patients in
the zalutumumab group versus none in the control group),
anemia (6% and 5%, resp.), and pneumonia (5% and 2%,
resp.). Grade 3/4 infections occurred in 15% of the patients
in the zalutumumab group and 9% in the control group
[36].
2.3.4. Panitumumab. Panitumumab is a fully human IgG2
EGFR-directed antibody. Its pharmacokinetic proﬁle allows
a convenient three-week administration. In the SPECTRUM
trial (Study of Panitumumab Eﬃcacy in Patients With
Recurrent and/or Metastatic Head and Neck Cancer), [37]
657 patients were randomized between cisplatin 100mg/m2
on day 1, followed by 5-ﬂuorourcacil 1000mg/m2/day for 4
days or the same chemotherapy plus panitumumab 9mg/kg
administeredonday1.Cycleswererepeatedevery3weeksup
to a maximum of 6 cycles. Patients receiving panitumumab
without progression after 6 cycles could continue panitu-
mumabmonotherapy untilprogression. Patientswereallow-
ed to switch from cisplatin to carboplatin (AUC 5) during
treatment for speciﬁc cisplatin-related toxicities, such as
grade ≥2 neurotoxicity or a drop in creatinine clearance to
<50mL/min.Overallsurvivalwastheprimaryendpoint.The
median OS in the combined arm was 11.1 months compared
to 9.0 months in the chemotherapy alone arm (HR = 0.87;
95% CI: 0.73–1.05; P = 0.14). However, there was a statisti-
cally signiﬁcant diﬀerence in response rate (36% versus 25%;
P = 0.007) and PFS (median 5.8 months versus 4.6 months;
HR = 0.78; 95% CI: 0.66–0.92; P = 0.004) in favour of the
panitumumab-containing arm. Although the SPECTRUM
trial failed to meet its primary endpoint, the results are
nevertheless consistent with the outcome of the EXTREME
trial.
2.3.5. Nimotuzumab. Nimotuzumab is a humanized EGFR
targeting monoclonal antibody which was studied in mul-
tiple phase II trials. A weekly ﬁxed dose of 200mg was
established as recommended dose for use in combination
with radiotherapy in LA SCCHN. No grade 3/4 adverse
eventswerereportedinapilotstudyofweeklynimotuzumab
(200mg), radiotherapy (66Gy in 33 fractions/2Gy per
fraction over 6.5 weeks) and weekly cisplatin (40mg/m2)
in 17 patients with LA SCCHN [38]. Rodr´ ıguez et al. [39]
enrolled106patientswithinoperableLASCCHNinadouble
blind, randomized phase II trial. The primary endpoint of
the trial was the complete response rate, which was 59.5%
with nimotuzumab versus 34.2% with placebo (P = 0.028).
Babu et al. [40] also conducted a randomized phase II trial
inpatientswithLASCCHN.Ninety-twopatientswereenrol-
led,and 76 wereevaluable.Patients included in group Awere
treated with radiation (60–66Gy) with or without nimo-
tuzumab. At 48 months of followup, OS was 34% with RT
plus nimotuzumab versus 13% with radiotherapy alone.
Patients included in group B were treated with CRT
(60–66Gy plus weekly cisplatin at a dose of 50mg) with or
withoutweeklynimotuzumab.At48monthsoffollowup,OS
rate was 47% with CRT plus nimotuzumab versus 21% with
CRT (P = 0.01).8 ISRN Oncology
2.4. Tyrosine Kinase Inhibitors. Tyrosine kinase inhibitors
which have been tested in SCCHN include geﬁtinib and
erlotinib, which are reversible speciﬁc EGFR TKIs, lapatinib,
a reversible dual EGFR/Her2 TKI, afatinib, an irreversible
dualEGFR/Her2TKI,andPF-00299804,apotentirreversible
pan-HER TKI.
2.4.1. Geﬁtinib and Erlotinib
Recurrent/Metastatic SCCHN. Argiris et al. [41] planned to
randomize 330 patients to receive docetaxel 35mg/m2 on
days 1, 8, and 15 every 28 days either plus placebo or in
combinationwithgeﬁtinib250mg/day.Thedatamonitoring
committee recommended early stopping of enrollment after
inclusion of 270 patients because there was <5% chance to
meet the primary endpoint (overall survival). Eligible were
patients who were previously treated with chemotherapy for
R/M SCCHN (73% of the patients) and patients previously
untreated for R/M SCCHN either with a poor performance
status (ECOG 2) or in case of relapse within 6 months
after chemotherapy given as part the primary treatment with
curative intent. Median OS was 6.8 months with docetaxel
plus placebo versus 6.2 months with docetaxel plus geﬁtinib
(HR 0.99; 95% CI: 0.75–1.31; P = 0.97). The time to pro-
gression was signiﬁcantly longer with the addition of geﬁ-
tinib (median 3.5 months versus 2.1 months; HR 0.69; 95%
CI: 0.49–0.99; P = 0.047). In the IMEX trial [42], 486 R/M
SCCHN patients were randomly assigned to oral geﬁtinib
250mg/day, geﬁtinib 500mg/day, or methotrexate 40mg/m2
intravenously weekly. Physicians and patients were blinded
to the geﬁtinib dose. Two coprimary analyses compared OS
between each geﬁtinib dose and methotrexate. Patients were
stratiﬁed into two groups: group A (n = 256) consisted
of patients who had stable or progressive disease after at
least two cycles of platinum-based chemotherapy for recur-
rent disease; group B (n = 230) consisted of patients
who were considered unsuitable for platinum-containing
chemotherapy. Neither geﬁtinib 250mg/day nor geﬁtinib
500mg/day improved OS compared with methotrexate (HR:
1.22; 95% CI: 0.95–1.57; P = 0.12; HR: 1.12; 95% CI: 0.87–
1.43; P = 0.39, resp.). Median OS was 5.6, 6.0, and 6.7
monthsinthegeﬁtinib250mg/day,geﬁtinib500mg/day,and
methotrexate groups, respectively. In group A, OS was signi-
ﬁcantly longer with methotrexate (HR for death: geﬁti-
nib 250mg versus methotrexate: 1.62; P = 0.01; geﬁtinib
500mg versus methotrexate: 1.5; P = 0.02). Tumor hemo-
rrhage-type events were more common with geﬁtinib (250
and 500mg) than with methotrexate (8.9%, 11.4%, and
1.9%, resp.). The most common adverse events were rash,
diarrhea, cancer pain, nausea, and vomiting with geﬁtinib,
and stomatitis, nausea, and constipation with methotrexate.
The OS with geﬁtinib in the IMEX trial was similar to
what was observed in earlier uncontrolled phase II studies
with geﬁtinib or erlotinib [43–46]. Dose escalation of geﬁt-
inib adaptive to skin toxicity grade did not improve response
rate in a phase II trial conducted by Perez et al. [47].
Locoregionally Advanced SCCHN. William Jr. et al. [48]
randomized 34 patients with resectable SCCHN to receive
erlotinib daily for 2 to 8 weeks prior to surgery at standard
(150mg) or high doses (200mg in never/former smokers,
and 300mg in current smokers). There were no grade 4 tox-
icities or erlotinib-related surgical complications. Response
ratesweredocumentedin18%and29%ofthepatientsinthe
low-and high-dose arms, respectively, suggesting that a sub-
group of previously untreated SCCHN is highly sensitive to
EGFR tyrosine kinase inhibition.
Hayes et al. [49] randomly assigned 128 patients with
LA SCCHN to receive either cisplatin 100mg/m2 on days
1, 22, and 43 combined with 70Gy of radiotherapy (arm
A) or the same treatment plus 150mg of erlotinib starting
one week before CRT and continued until the completion of
radiotherapy (arm B). Serious adverse events were observed
in 33% and 32% of the patients in arm A and B, respectively.
Most common serious adverse events were nausea, vomiting,
anddehydrationandaccountedfor30%ofallSAEsreported,
with no diﬀerence between arms. Eﬃcacy data are pending.
Gregoire et al. [50] enrolled 226 patients in a randomized
phase II trial testing the value of geﬁtinib during and/or after
CRT in LA SCCHN. Patients received either placebo during
CRT followed by adjuvant placebo, or geﬁtinib 250mg
or 500mg/day during CRT followed by placebo, geﬁtinib
250mg or 500mg/day during and after CRT, or placebo
during CRT followed by adjuvant geﬁtinib at a dose of
250mg or 500mg/day. Adjuvant therapy was administered
for a maximum of 2 years. There was no diﬀerence in
2-year local disease control rate (primary endpoint) between
the 7 treatment arms. Soulieres et al. [51] evaluated the
toxicity and recommended dose for adjuvant erlotinib after
deﬁnitive CRT for LA SCCHN. No dose limiting toxicities
were observed at a daily dose of 100 or 150mg for 6 months.
At the 150mg dose, 46% of the patients received ≥90% dose
intensity. The approach can be considered for a phase III
trial.
2.4.2. Dual EGFR/Her2- and Pan HER-Inhibitors. Encour-
aging preliminary results in R/M SCCHN after failure of a
platinum-containing therapy were reported with afatinib, a
dual EGFR/Her2 irreversible tyrosine kinase inhibitor, which
was compared to single-agent cetuximab in a randomized
phase II study. The overall response rate with afatinib com-
paredfavorablytotheORRwithcetuximab[52].Harrington
et al. [53] enrolled 67 patients into a randomized, placebo-
controlled, phase II trial, exploring the potential beneﬁt
of adding lapatinib to CRT in patients with LA SCCHN.
Lapatinib (1500mg/day) or placebo were started 1 week
before CRT (70Gy in 35 fractions over 7 weeks plus cisplatin
100mg/m2 on days 1, 22, and 43) and continued during and
afterCRTuntildiseaseprogression.Theadditionoflapatinib
did not impair the timely administration of CRT and did not
leadtoanincreaseinmucositisandradiationdermatitis.The
complete response rate at 6 months after treatment (primary
endpoint) was 36% with placebo and 53% with lapatinib.
The PFS rates at 12 months were 45 and 59%, respectively.
Del Campo et al. [54] treated 107 patients with LA SCCHN
with either lapatinib or placebo for 2–6 weeks prior to CRT.
The overall response rate before CRT in the 40 patients who
received >4 weeks of lapatinib was 17%.ISRN Oncology 9
Siuetal.[55]enrolled69 patientsin aphaseIIstudy with
PF-00299804 at a dose of 45mg QD, in previously untreated
R/M SCCHN. Grade 3 adverse events were diarrhea (16%),
fatigue (9%), acneiform dermatitis (7%), and hand-foot
reaction (4%). The ORR and DCR were 12.7 and 60%,
respectively. Median PFS and OS were 2.8 and 8.3 months,
respectively.
3. VEGFR-DirectedTherapies
A meta-analysis conducted by Kyzas et al. [56] demonstrated
that VEGF protein overexpression, as detected with immu-
nohistochemistry, is associated with a worse OS in patients
with SCCHN.
3.1. Bevacizumab. Bevacizumab is a humanized IgG1 mon-
oclonal antibody that binds selectively to all isoforms of
human VEGF and neutralizes the biologic activities of VEGF
by blocking the binding of VEGF to its receptors on the sur-
face of endothelial cells. Bevacizumab enhances the activity
of chemotherapy in SCCHN xenografts [57, 58].
Argiris et al. [59] combined pemetrexed 500mg/m2 and
bevacizumab 15mg/kg given intravenously every 21 days
until disease progression in 40 patients presenting with pre-
viously untreated R/M SCCHN. The median TTP (primary
endpoint) was 5 months, and the median OS was 11.3
months. In 37 evaluable patients, the ORR was 30%, and the
DCR was 86%. Grade ≥ 3 bleeding events occurred in 6/40
patients (15%) and was fatal in 2 (5%) [59]. Bevacizumab,
10mg/kg, administered on day 1 of each 2-week cycle, can
be safely combined with FHX CRT regimen, consisting of
ﬁve 2-week cycles of hydroxyurea 500mg orally bid, 5-FU
600mg/m2/day administered as a continuous infusion, and
radiotherapy,1.5Gybidfor5daysfollowedby9dayswithout
therapy (FHX), in patients with poor prognosis SCCHN
[60]. Salama et al. [61] conducted a randomized phase II
study evaluating the impact of adding bevacizumab (B) to
the FHX regimen. Eligible were patients with T1-3, N0-1
and T4, N0-1 SCCHN. The study was terminated early after
enrollment of 26 patients following unexpected locoregional
progression. All locoregional progression occurred in T4
tumors randomized to BFHX. Two patients receiving BFHX
died during therapy, and one died shortly after therapy. Two-
year OS was 89% in patients treated with FHX and 58% in
patients treated with BFHX. These unexpected ﬁndings are
not well understood and could be due to chance, given the
small sample size. Harari et al. [62] demonstrated the safety
and feasibility of combining CRT (70Gy in 33 fractions and
weekly cisplatin, 30mg/m2) with bevacizumab weeks −3, 1,
4, and 7 with dose escalation from 5 to 10 to 15mg/kg in 10
patients with LA SCCHN. Several patients manifested tumor
regression following administration of bevacizumab alone.
No dose-limiting toxicities (DLTs) were observed.
3.2. Tyrosine Kinase Inhibitors. Sorafenib and sunitinib are
oral inhibitors of multiple kinases including the recep-
tor tyrosine kinases of vascular endothelial growth factor
(VEGF) receptor. Phase II data with both agents in R/M
SCCHN are extremely disappointing. Elser et al. [63]
treated 27 patients with R/M SCCHN or nasopharyngeal
carcinoma (7 patients), who had received ≤1 chemotherapy
for recurrent or metastatic disease with sorafenib 400mg
twice daily on a continuous basis. The treatment was well
toleratedwithfewgrade3or4toxicities.However,anticancer
activity was modest. One patient achieved a partial response
(3.7%). Disease control rate was 40.7%. The median TTP
was 1.8 months, and median OS was 4.2 months. The
same regimen was evaluated in the Southwest Oncology
Group study S0420 [64], which enrolled 41 R/M SCCHN
patients who had not received prior chemotherapy for R/M
disease. The overall conﬁrmed response rate was a mere
2%. However, the estimated median PFS was 4 months, and
the estimated median OS was 9 months. In the GORTEC
2006–01 study [65], 38 patients with R/M SCCHN received
sunitinib 37.5mg/day on a continuous basis. Forty-ﬁve
percent and 3% of the patients had received one and two
prior chemotherapy regimens for R/M disease, respectively.
Local complications, including the appearance or worsening
of tumor skin ulceration or tumor ﬁstula, were recorded in
39.5% of the patients, and a fatal arterial bleeding in the
head and neck region occurred in 10.5% of the patients.
The ORR and DCR were 2.6 and 50%, respectively. Median
PFS and OS were 2 and 3.4 months, respectively. Fountzilas
et al. [66] treated 17 R/M SCCHN patients with sunitinib
50mg per day administrated in 4-week cycles followed
by a rest period of 2 weeks as ﬁrst-line treatment for
R/M disease and observed no objective responses. Disease
control rate was 18%, median TTP was 2.3 months, and
median OS was 4 months. The same intermittent sunitinib
regimen was used by Choong et al. [67] who observed an
ORR of 4.5% and a DCR of 27.3%. Sabichi et al. [68]
combined paclitaxel, carboplatin AUC 6, administered every
3 weeks, and sorafenib 400mg bid, days 2–19, in patients
with R/M SCCHN. Twenty-eight patients were enrolled and
22 were evaluable for response. The ORR and DCR were
68 and 91%, respectively. Vandetanib is an inhibitor of
vascular endothelial growth factor receptor-2 (VEGFR-2),
EGFR, and rearranged during transfection (RET) tyrosine
kinases. It restores HNSCC cells’ sensitivity to cisplatin and
radiation in vitro and in vivo [69]. As a single agent, it
has antiproliferative eﬀects on SCCHN cells in vitro and
inhibits tumor growth in nude mice orthotopically injected
with human SCCHN cells [70]. Vandetanib can be safely
combined with radiotherapy (2.2Gy/d, 5 days/week up to a
total dose of 66Gy) or radiotherapy (2Gy/d, 5 days/week up
to a total dose of 70Gy) plus weekly 30mg/m2 of cisplatin
[71].
4.Other Targets
4.1. Heat-Shock Protein 90. Heat-shock protein 90 (HSP90)
is a protein which chaperones multiple client oncoproteins
involved in tumor progression. Okui et al. [72]i n v e s t i g a t e d
the antitumor eﬀect of the novel HSP90 inhibitor NVP-
AUY922 against oral SCC (OSCC). NVP-AUY922 inhibited
the proliferation of OSCC cells in vitro and induced a
robust antitumor response and suppressed p-Akt and VEGF
expression in an HSC-2 xenograft model.10 ISRN Oncology
4.2. Sirtuin. Several sirtuin family members (SIRT1-7) func-
tion either as nicotinamide adenine dinucleotide (NAD)-
dependent deacetylases or as ADP-ribosyl transferases and
are involved in carcinogenesis [73]. Alhazzazi et al. [74]
demonstrated that SIRT3 is overexpressed in OSCC in
vitro and in vivo and that SIRT3 downregulation inhibits
OSCC cell growth and proliferation and increased OSCC cell
sensitivity to radiation and cisplatin treatments in vitro.
4.3. Histone Deacetylase. Histone deacetylases are enzymes
involved in remodeling of chromatin by deacetylating the
lysineresiduesandplayapivotalroleinepigeneticregulation
of gene expression. There is extensive preclinical evidence
supporting the testing of HDAC inhibitors in SCCHN.
HDAC inhibitors have radio-enhancing properties [75, 76],
increase the susceptibility of SCC cell lines to cisplatin in
vitro[77, 78], and inhibit tumor growth in xenograft models
of SCCHN [79]. Bruzzese et al. [80] demonstrated that the
histone deacetylase inhibitor vorinostat in combination with
the EGFR tyrosine kinase inhibitor geﬁtinib induced syner-
gistic inhibition of proliferation, migration, and invasion as
wellasinductionofapoptosisinSCCHNcells,includingcells
resistant to geﬁtinib.
4.4. Aurora A and B. High expression of aurora A or B is
associated with a worse outcome in SCCHN [81–86].
Hoellein et al. [87] combined a dual aurora A/aurora B
inhibitor with cetuximab in SCCHN cell lines in vitro and
observed at least an additive eﬀect. Aurora kinase inhibition
w a sa b l et oo v e r c o m er e s i s t a n c et oc e t u x i m a b[ 87].
4.5. Mammalian Target of Rapamycin. Preclinical data
strongly support the testing of mammalian target of rapa-
mycin (mTOR) in SCCHN [88–90]. Activation of mTOR is
observed in the majority of SCCHN [91] and is associated
with a poor outcome [92]. Patel et al. [93] found that inhibi-
tionofmTORdiminishedlymphangiogenesisintheprimary
tumors and prevented the dissemination of SCCHN cancer
cells to the cervical lymph nodes in an orthotopic mouse
model [93]. Temsirolimus enhances the growth-inhibiting
eﬀects of the combination of bevacizumab, cetuximab, and
irradiation in head and neck cancer xenografts [94]. Aissat
et al. [95] demonstrated that rapamycin displays antiprolif-
erative eﬀectsandinducesapoptosis inSCCHNcelllinesand
thatcombinationofrapamycinwithpaclitaxelorcarboplatin
displayed synergistic and additive eﬀects [95]. Temsirolimus
appeared to be a more potent radiosensitizer than cisplatin
in mice bearing squamous cell carcinoma xenografts [96]. In
a pharmacodynamic evaluation of temsirolimus in SCCHN
patients, Ekshyyan et al. found a signiﬁcant inhibition of
the mTOR pathways in tumor cells and in peripheral blood
mononuclearcells[97].Everolimus10mg/day,days1–21can
besafelycombinedwithcisplatin20mg/m2,da ys1,8,and15
of a 28-day cycle in patients with solid tumors [98].
4.6. c-Src. c-Src is a nonreceptor cytoplasmic tyrosine kinase
that regulates signals from cell surface molecules and that
plays a key role in modulating multiple cellular functions by
activatingthesignaltransducerandactivatoroftranscription
(STAT) family of transcription factors. Although preclinical
data provided a rationale for testing c-Scr inhibitors in
SCCHN, the outcome with single-agent c-Scr inhibitors in
patients with R/M SCCHN was disappointing. Brooks et al.
[99]treated15R/MSCCHNpatientswithdasatinib,apotent
inhibitor ofSrc-familykinases EphA2, atadose 100mg twice
daily. No objective responses were observed and the median
PFS was less than 1 month. Saracatinib is also an orally
available Src kinase inhibitor which was administered to 9
R/M SCCHN patients at a daily dose of 175mg [100]. Eight
patients had disease progression within the ﬁrst eight-week
cycle, and one patient was removed from the study after 11
days due to rapid clinical decline. The study was closed early
due to lack of eﬃcacy according to the early stopping rule
[100].
4.7. Phosphatidylinositol-3-Kinase. Rampias et al. [101]d e -
tected HRAS mutations in 29% of 105 SCCHN specimens.
Four percent of the specimens harbored PIK3CA mutations.
Cell lines bearing HRAS or PIK3CA mutations are resistant
to cetuximab. This resistance can be overcome by addition of
a PI3K inhibitor.
4.8. Nuclear Factor Kappa B. Nuclear factor kappa B is over-
e x p r e s s e di nS C C H N ,a n dN F - κB expression is associated
with a poor prognosis. Bortezomib is a small-molecule pro-
teasome inhibitor which aﬀects multiple signaling pathways
including NF-κB. Chung et al. treated 25 R/M SCCHN
patientswithbortezomib1.6mg/m2 anddocetaxel40mg/m2
on days 1 and 8 of a 21-day cycle and observed a ORR and
D C Ro f5a n d5 2 % ,r e s p e c t i v e l y .
5. Combination of Targeted Agents
Cohen et al. [102] combined erlotinib 150mg/day and
bevacizumab IV every 3 weeks. As no dose-limiting toxicities
were observed in the phase I portion of the study which
included 10 patients up to the maximum planned dose
of 15mg/kg of bevacizumab, 46 additional patients were
treated at that dose level. Forty-eight percent of the patients
had received prior chemotherapy for recurrent/metastatic
disease. The combination was well tolerated. Three patients
(5%) experienced serious bleeding events. The observed
response rate was 15% with 4 complete responses allowing
rejection of the null hypothesis that the response rate is ≤5%
and the percentage of patients not progressing within two
months is ≤30%. The median OS and PFS were 7.1 and 4.1
months, respectively. Higher ratios of phosphorylated over
total VEGF receptor-2 and EGFR in pretreatment biopsies
were associated with complete response (P = 0.036 and P =
0.036, resp.) and tumor shrinkage (P = 0.007 and P = 0.008,
resp.) in a subset of 11 subjects with available tissue [102].
The feasibility and eﬃcacy of adding bevacizumab and
erlotinib to concurrent CRT in patients with LA SCCHN was
evaluated in a phase II trial conducted by the Sarah Cannon
oncology research consortium including 60 previously
untreated patients [103]. The treatment consisted of induc-
tion chemotherapy with 6 weeks of paclitaxel, carboplatin,
infusional 5-ﬂuorouracil, and bevacizumab, which wasISRN Oncology 11
followed by radiation therapy, weekly paclitaxel, bevaci-
zumab, and erlotinib. After a median followup of 32 months,
the estimated 3-year PFS and OS rates are 71% and 82%,
respectively. Grade 3/4 mucosal toxicity occurred frequently
(88%) during combined modality. No unexpected toxicity
resulted from the addition of bevacizumab and erlotinib.
Integrins promote and regulate endothelial cell prolifera-
tion, migration, invasion, and survival in tumors, securing
vascularisation and vascular remodeling in tumors. Cilen-
gitide is a selective inhibitor of the αvβ3/5 integrins.
ADVANTAGE [104] is a phase I/II trial evaluating cilengitide
in combination with cetuximab, cisplatin and 5-ﬂuorouracil
in patients with R/M SCCHN. No DLTs were observed in
the phase I part of the study which tested cilengitide (500,
1000,and2000mg)twiceweeklywithstandarddosesofcetu-
ximab, cisplatin and 5-ﬂuorouracil. Cilengitide 2000mg was
considered safe and was selected for the subsequent rando-
mised phase II part assessing PFS [104].
6. Conclusion
The road from preclinical evidence to clinical use is long
and bumpy, and a large number of targeted agents are still
at the start of the race. Some others reached the last stretch
but stumbled on one of the last hurdles in phase II, or even
phaseIIItrials.Thusfar,onlytheEGFR-directedmonoclonal
antibody cetuximab has made it to the ﬁnish and is currently
approved for the treatment of locoregionally advanced and
recurrent/metastatic SCCHN, by the regulatory agencies of
the United States and Europe.
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